Wedbush set a $79.00 target price on Aimmune Therapeutics (NASDAQ:AIMT) in a report released on Thursday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on AIMT. ValuEngine upgraded Zillow Group from a hold rating to a buy rating in a research report on Thursday. Cantor Fitzgerald restated a buy rating and issued a $27.00 price target on shares of Spero Therapeutics in a research report on Thursday, May 9th. Zacks Investment Research upgraded DLH from a sell rating to a hold rating in a research report on Tuesday. BidaskClub upgraded Zillow Group from a buy rating to a strong-buy rating in a research report on Tuesday, July 2nd. Finally, Credit Suisse Group decreased their price target on Athene from $67.00 to $57.00 and set an outperform rating on the stock in a research report on Tuesday, May 21st. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of Hold and a consensus target price of $46.43.

AIMT stock traded up $0.25 during trading hours on Thursday, hitting $18.76. 449,250 shares of the stock were exchanged, compared to its average volume of 462,527. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -5.11 and a beta of -0.06. The firm has a 50-day moving average price of $20.19. Aimmune Therapeutics has a 12 month low of $16.95 and a 12 month high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.07. Equities research analysts anticipate that Aimmune Therapeutics will post -3.77 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cable Hill Partners LLC increased its position in shares of Aimmune Therapeutics by 81.7% in the first quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Advisor Group Inc. increased its position in shares of Aimmune Therapeutics by 84.6% in the fourth quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 796 shares during the period. Manchester Capital Management LLC bought a new position in shares of Aimmune Therapeutics in the first quarter worth $27,000. Pearl River Capital LLC bought a new position in shares of Aimmune Therapeutics in the first quarter worth $28,000. Finally, Marshall Wace North America L.P. acquired a new stake in Aimmune Therapeutics in the first quarter valued at about $32,000. Institutional investors own 76.12% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Recommended Story: What is a put option?

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.